49 results on '"Westerhout, Cynthia M."'
Search Results
2. Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial.
- Author
-
Ezekowitz, Justin, Alemayehu, Wendimagegn, Edelmann, Frank, Ponikowski, Piotr, Lam, Carolyn S.P., O'Connor, Christopher M., Butler, Javed, Corda, Stefano, McMullan, Ciaran J., Westerhout, Cynthia M., Voors, Adriaan A., Mentz, Robert J., and Armstrong, Paul W.
- Subjects
HEART failure patients ,VENTRICULAR ejection fraction ,DIURETICS ,TREATMENT effectiveness ,HEART failure - Abstract
Aims: In VICTORIA, vericiguat compared with placebo reduced the risk of cardiovascular death (CVD) and heart failure hospitalization (HFH) in patients enrolled after a worsening heart failure (WHF) event. We examined clinical outcomes and efficacy of vericiguat as it relates to background use of loop diuretics in patients with WHF. Methods and results: We calculated the total daily loop diuretic dose equivalent to furosemide dosing at randomization and categorized these as: no loop diuretic, 1–39, 41–80, 40, and >80 mg total daily dose (TDD). The primary composite outcome of CVD/HFH and its components were evaluated based on TDD loop diuretic and expressed as adjusted hazard ratios with 95% confidence intervals. Post‐randomization rates of change in TDD were also examined. Of 4974 patients (98% of the trial) with diuretic dose information available at randomization, 540 (10.8%) were on no loop diuretic, 647 (13.0%) were on 1–39, 1633 (32.8%) were on 40, 1185 (23.8%) were on 41–80, and 969 (19.4%) were on >80 mg TDD. Patients with higher TDD had a higher rate of primary and secondary clinical outcomes. There were no significant interactions with TDD at randomization and efficacy of vericiguat versus placebo for any outcome (all pinteraction > 0.5). Post‐randomization diuretic dose changes for vericiguat and placebo showed similar rates of up‐titration (19.6 and 20.2/100 person‐years), down‐titration (16.8 and 18.1/100 person‐years), and stopping diuretics (22.9 and 24.2/100 person‐years). Conclusions: Loop diuretic TDD at randomization was independently associated with worse outcomes in this high‐risk population. The efficacy of vericiguat was consistent across the range of diuretic doses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Relationship between baseline electrocardiographic measurements and outcomes in patients with high‐risk heart failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial.
- Author
-
Yogasundaram, Haran, Zheng, Yinggan, Ly, Eric, Ezekowitz, Justin, Ponikowski, Piotr, Lam, Carolyn S.P., O'Connor, Christopher, Blaustein, Robert O., Roessig, Lothar, Temple, Tracy, Westerhout, Cynthia M., Armstrong, Paul W., and Sandhu, Roopinder K.
- Subjects
BRAIN natriuretic factor ,HEART failure ,HEART failure patients ,VENTRICULAR ejection fraction ,RIGHT ventricular hypertrophy - Abstract
Aims: Whether electrocardiographic (ECG) measurements predict mortality in chronic heart failure with reduced ejection fraction (HFrEF) is unknown. Methods and results: We studied 4880 patients from the Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial with a baseline 12‐lead ECG. Associations between ECG measurements and mortality were estimated as hazard ratios (HR) and adjusted for the Meta‐Analysis Global Group in Chronic Heart Failure (MAGGIC) risk score, N‐terminal pro‐B‐type natriuretic peptide, and index event. Select interactions between ECG measurements, patient characteristics and mortality were examined. Over a median of 10.8 months, there were 824 cardiovascular (CV) deaths (214 sudden) and 1005 all‐cause deaths. Median age was 68 years (interquartile range [IQR] 60–76), 24% were women, median ejection fraction was 30% (IQR 23–35), 41% had New York Heart Association class III/IV, and median MAGGIC score was 24 (IQR 19–28). After multivariable adjustment, significant associations existed between heart rate (per 5 bpm: HR 1.02), QRS duration (per 10 ms: HR 1.02), absence of left ventricular hypertrophy (HR 0.64) and CV death, and similarly so with all‐cause death (HR 1.02; HR 1.02; HR 0.61, respectively). Contiguous pathologic Q waves were significantly associated with sudden death (HR 1.46), and right ventricular hypertrophy with all‐cause death (HR 1.44). The only sex‐based interaction observed was for pathologic Q waves on CV (men: HR 1.05; women: HR 1.64, pinteraction = 0.024) and all‐cause death (men: HR 0.99; women: HR 1.57; pinteraction = 0.010). Whereas sudden death doubled in females, it did not differ among males (male: HR 1.25, 95% confidence interval [CI] 0.87–1.79; female: HR 2.50, 95% CI 1.23–5.06; pinteraction = 0.141). Conclusion: Routine ECG measurements provide additional prognostication of mortality in high‐risk HFrEF patients, particularly in women with contiguous pathologic Q waves. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat.
- Author
-
Armstrong, Paul W., Yinggan Zheng, Lund, Lars H., Butler, Javed, Troughton, Richard W., Emdin, Michele, Lam, Carolyn S. P., Ponikowski, Piotr, Blaustein, Robert O., O'Connor, Christopher M., Roessig, Lothar, Voors, Adriaan A., Ezekowitz, Justin A., and Westerhout, Cynthia M.
- Published
- 2023
- Full Text
- View/download PDF
5. Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial.
- Author
-
Ezekowitz, Justin A., McMullan, Ciaran J., Westerhout, Cynthia M., Piña, Ileana L., Lopez-Sendon, Jose, Anstrom, Kevin J., Hernandez, Adrian F., Lam, Carolyn S. P., O'Connor, Christopher M., Pieske, Burkert, Ponikowski, Piotr, Roessig, Lothar, Voors, Adriaan A., Koglin, Joerg, Armstrong, Paul W., and Butler, Javed
- Published
- 2023
- Full Text
- View/download PDF
6. STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial.
- Author
-
Van de Werf, Frans, Ristić, Arsen D., Averkov, Oleg V., Arias-Mendoza, Alexandra, Lambert, Yves, Kerr Saraiva, José F., Sepulveda, Pablo, Rosell-Ortiz, Fernando, French, John K., Musić, Ljilja B., Vandenberghe, Katleen, Bogaerts, Kris, Westerhout, Cynthia M., Pagès, Alain, Danays, Thierry, Bainey, Kevin R., Sinnaeve, Peter, Goldstein, Patrick, Welsh, Robert C., and Armstrong, Paul W.
- Published
- 2023
- Full Text
- View/download PDF
7. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy.
- Author
-
Pieske, Burkert, Pieske‐Kraigher, Elisabeth, Lam, Carolyn S.P., Melenovský, Vojtěch, Sliwa, Karen, Lopatin, Yuri, Arango, Juan Luis, Bahit, M. Cecilia, O'Connor, Christopher M., Patel, Mahesh J., Roessig, Lothar, Morris, Daniel A., Kropf, Martin, Westerhout, Cynthia M., Zheng, Yinggan, and Armstrong, Paul W.
- Subjects
HEART failure patients ,VENTRICULAR ejection fraction ,ECHOCARDIOGRAPHY ,HEART failure ,CARDIOVASCULAR disease related mortality - Abstract
Aim: Vericiguat significantly reduced the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death in the VICTORIA trial. It is unknown if these outcome benefits are related to reverse left ventricular (LV) remodelling with vericiguat in patients with HF with reduced ejection fraction (HFrEF). The aim of this study was to compare the effects of vericiguat versus placebo on LV structure and function after 8 months of therapy in patients with HFrEF. Methods and results: Standardized transthoracic echocardiography (TTE) was performed at baseline and after 8 months of therapy in a subset of HFrEF patients in VICTORIA. The co‐primary endpoints were changes in LV end‐systolic volume index (LVESVI) and LV ejection fraction (LVEF). Quality assurance and central reading were performed by an echocardiographic core laboratory blinded to treatment assignment. A total of 419 patients (208 vericiguat, 211 placebo) with high‐quality paired TTE at baseline and 8 months were included. Baseline clinical characteristics were well balanced between treatment groups and echocardiographic characteristics were representative of patients with HFrEF. LVESVI significantly declined (60.7 ± 26.8 to 56.8 ± 30.4 ml/m2; p < 0.01) and LVEF significantly increased (33.0 ± 9.4% to 36.1 ± 10.2%; p < 0.01) in the vericiguat group, but similarly in the placebo group (absolute changes for vericiguat vs. placebo: LVESVI −3.8 ± 15.4 vs. −7.1 ± 20.5 ml/m2; p = 0.07 and LVEF +3.2 ± 8.0% vs. +2.4 ± 7.6%; p = 0.31). The absolute rate per 100 patient‐years of the primary composite endpoint at 8 months tended to be lower in the vericiguat group (19.8) than the placebo group (29.6) (p = 0.07). Conclusions: In this pre‐specified echocardiographic study, significant improvements in LV structure and function occurred over 8 months in both vericiguat and placebo in a high‐risk HFrEF population with recent worsening HF. Further studies are warranted to define the mechanisms of vericiguat's benefit in HFrEF. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. The empirical estimate of the survival and variance using a weighted composite endpoint.
- Author
-
Nabipoor, Majid, Westerhout, Cynthia M., Rathwell, Sarah, and Bakal, Jeffrey A.
- Subjects
KAPLAN-Meier estimator ,TREATMENT effectiveness ,CONFIDENCE intervals - Abstract
Background: Composite endpoints for estimating treatment efficacy are routinely used in several therapeutic areas and have become complex in the number and types of component outcomes included. It is assumed that its components are of similar asperity and chronology between both treatment arms as well as uniform in magnitude of the treatment effect. However, these assumptions are rarely satisfied. Understanding this heterogeneity is important in developing a meaningful assessment of the treatment effect. Methods: We developed the Weighted Composite Endpoint (WCE) method which uses weights derived from stakeholder values for each event type in the composite endpoint. The derivation for the product limit estimator and the variance of the estimate are presented. The method was then tested using data simulated from parameters based on a large cardiovascular trial. Variances from the estimated and traditional approach are compared through increasing sample size. Results: The WCE method used all of the events through follow-up and generated a multiple recurrent event survival. The treatment effect was measured as the difference in mean survivals between two treatment arms and corresponding 95% confidence interval, providing a less conservative estimate of survival and variance, giving a higher survival with a narrower confidence interval compared to the traditional time-to-first-event analysis. Conclusions: The WCE method embraces the clinical texture of events types by incorporating stakeholder values as well as all events during follow-up. While the effective number of events is lower in the WCE analysis, the reduction in variance enhances the ability to detect a treatment effect in clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Predictors and associated clinical outcomes of low cardiac output syndrome following cardiac surgery: insights from the LEVO-CTS trial.
- Author
-
Kochar, Ajar, Zheng, Yinggan, van Diepen, Sean, Mehta, Rajendra H, Westerhout, Cynthia M, Mazer, David Cyril, Duncan, Andra I, Whitlock, Richard, Lopes, Renato D, Argenziano, Michael, de Varennes, Benoit, Alexander, John H, Goodman, Shaun G, and Fremes, Stephen
- Published
- 2022
- Full Text
- View/download PDF
10. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.
- Author
-
Senni, Michele, Alemayehu, Wendimagegn G., Sim, David, Edelmann, Frank, Butler, Javed, Ezekowitz, Justin, Hernandez, Adrian F., Lam, Carolyn S.P., O'Connor, Christopher M., Pieske, Burkert, Ponikowski, Piotr, Roessig, Lothar, Voors, Adriaan A., Westerhout, Cynthia M., McMullan, Ciaran, Armstrong, Paul W., and VICTORIA Study Group
- Subjects
AMINOBUTYRIC acid ,COMBINATION drug therapy ,LEFT ventricular dysfunction ,HETEROCYCLIC compounds ,BIPHENYL compounds ,TREATMENT effectiveness ,RESEARCH funding ,HYPOTENSION ,HYPERKALEMIA ,ANGIOTENSIN receptors ,STROKE volume (Cardiac output) ,HEART failure - Abstract
Aim: We assessed a subset of the 5040 patients in VICTORIA receiving sacubitril/valsartan, either at randomization (n = 731) or post-randomization drop-in use (n = 425), to evaluate the relationship between the efficacy and safety of combination therapy with vericiguat.Methods and Results: The efficacy of vericiguat on the primary composite endpoint, heart failure (HF) hospitalization, and all-cause mortality was assessed. Safety outcomes included symptomatic hypotension, syncope, worsening renal function, and hyperkalaemia. At randomization, 731 patients received sacubitril/valsartan; they were more frequently from Western Europe or North America, had lower ejection fraction and systolic blood pressure, and more use of triple background HF therapy (65.9% vs. 58.6%), biventricular pacemakers (17.9% vs. 14.1%), or implantable cardioverter defibrillators (42.3% vs. 25.3%). For patients on versus not on sacubitril/valsartan at randomization, adjusted hazard ratios (95% confidence intervals) for vericiguat's treatment effect on the primary composite outcome, cardiovascular death, and HF hospitalization were 0.92 (0.71-1.19) versus 0.89 (0.80-0.98), 0.71 (0.45-1.12) versus 0.95 (0.82-1.11), and 0.98 (0.74-1.29) versus 0.87 (0.78-0.98), respectively. No significant interaction existed between sacubitril/valsartan and vericiguat's treatment effect (p-values for interaction: 0.81, 0.23 and 0.47, respectively). Post-randomization, more drop-in sacubitril/valsartan use occurred in those assigned to placebo (n = 238) versus vericiguat (n = 187) (p = 0.007). Symptomatic hypotension (21.0% vs. 23.1%; p = 0.41), renal dysfunction (29.9% vs. 31.9%; p = 0.50), and hyperkalaemia (10.3% vs. 7.9%; p = 0.20) in patients receiving sacubitril/valsartan (n = 992) for ≥3 months were not different by treatment arm.Conclusions: Concomitant use of sacubitril/valsartan for at least 3 months did not alter the efficacy of vericiguat and was similarly safe and tolerated in both study arms. Sacubitril/valsartan was initiated more frequently after randomization in patients assigned to placebo versus vericiguat.Clinical Trial Registration: ClinicalTrials.gov NCT02861534. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
11. Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes.
- Author
-
Shavadia, Jay S., Alemayehu, Wendimagegn, deFilippi, Christopher, Westerhout, Cynthia M., Tromp, Jasper, Granger, Christopher B., Armstrong, Paul W., and van Diepen, Sean
- Abstract
Early prediction of significant morbidity or mortality in patients with acute ST-segment elevation myocardial infarction (STEMI) represents an unmet clinical need. In phenotypically matched population of 139 STEMI patients (72 cases, 67 controls) treated with primary percutaneous coronary intervention, we explored associations between a 24-h relative change from baseline in the concentration of 91 novel biomarkers and the composite outcome of death, heart failure, or shock within 90 days. Additionally, we used random forest models to predict the 90-day outcomes. After adjustment for false discovery rate, the 90-day composite was significantly associated with concentration changes in 14 biomarkers involved in various pathophysiologic processes including: myocardial fibrosis/remodeling (collagen alpha-1, cathepsin Z, metalloproteinase inhibitor 4, protein tyrosine phosphatase subunits), inflammation, angiogenesis and signaling (interleukin 1 and 2 subunits, growth differentiation factor 15, galectin 4, trefoil factor 3), bone/mineral metabolism (osteoprotegerin, matrix extracellular phosphoglycoprotein and tartrate-resistant acid phosphatase), thrombosis (tissue factor pathway inhibitor) and cholesterol metabolism (LDL-receptor). Random forest models suggested an independent association when inflammatory markers are included in models predicting the outcomes within 90 days. Substantial heterogeneity is apparent in the early proteomic responses among patients with acutely reperfused STEMI patients who develop death, heart failure or shock within 90 days. These findings suggest the need to consider synergistic multi-biomarker strategies for risk stratification and to inform future development of novel post-myocardial infarction therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine.
- Author
-
Sharma, Abhinav, Yinggan Zheng, Ezekowitz, Justin A., Westerhout, Cynthia M., Udell, Jacob A., Goodman, Shaun G., Armstrong, Paul W., Buse, John B., Green, Jennifer B., Josse, Robert G., Kaufman, Keith D., McGuire, Darren K., Ambrosio, Giuseppe, Lee-Ming Chuang, Lopes, Renato D., Peterson, Eric D., Holman, Rury R., Zheng, Yinggan, and Chuang, Lee-Ming
- Subjects
TYPE 2 diabetes ,CLUSTER analysis (Statistics) ,CARDIOVASCULAR diseases ,INDIVIDUALIZED medicine ,PROPORTIONAL hazards models - Abstract
Objective: Phenotypic heterogeneity among patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) is ill defined. We used cluster analysis machine-learning algorithms to identify phenotypes among trial participants with T2DM and ASCVD.Research Design and Methods: We used data from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study (n = 14,671), a cardiovascular outcome safety trial comparing sitagliptin with placebo in patients with T2DM and ASCVD (median follow-up 3.0 years). Cluster analysis using 40 baseline variables was conducted, with associations between clusters and the primary composite outcome (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina) assessed by Cox proportional hazards models. We replicated the results using the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial.Results: Four distinct phenotypes were identified: cluster I included Caucasian men with a high prevalence of coronary artery disease; cluster II included Asian patients with a low BMI; cluster III included women with noncoronary ASCVD disease; and cluster IV included patients with heart failure and kidney dysfunction. The primary outcome occurred, respectively, in 11.6%, 8.6%, 10.3%, and 16.8% of patients in clusters I to IV. The crude difference in cardiovascular risk for the highest versus lowest risk cluster (cluster IV vs. II) was statistically significant (hazard ratio 2.74 [95% CI 2.29-3.29]). Similar phenotypes and outcomes were identified in EXSCEL.Conclusions: In patients with T2DM and ASCVD, cluster analysis identified four clinically distinct groups. Further cardiovascular phenotyping is warranted to inform patient care and optimize clinical trial designs. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
13. Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA).
- Author
-
Ezekowitz, Justin A. BCh,, Zheng, Yinggan MEd, Cohen-Solal, Alain, Melenovsky, Vojtech, Escobedo, Jorge, Butler, Javed, Hernandez, Adrian F. MHS, Lam, Carolyn S.P., O'Connor, Christopher M., Pieske, Burkert, Ponikowski, Piotr, Voors, Adriaan A., deFilippi, Christopher, Westerhout, Cynthia M., McMullan, Ciaran BCh, M, Roessig, Lothar, Armstrong, Paul W., Ezekowitz, Justin A, Zheng, Yinggan, and Melenovský, Vojtěch
- Published
- 2021
- Full Text
- View/download PDF
14. Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry.
- Author
-
Ezekowitz, Justin, Mentz, Robert J., Westerhout, Cynthia M., Sweitzer, Nancy K., Givertz, Michael M., Piña, Ileana L., O'Connor, Christopher M., Greene, Stephen J., McMullan, Ciaran, Roessig, Lothar, Hernandez, Adrian F., and Armstrong, Paul W.
- Published
- 2021
- Full Text
- View/download PDF
15. Computing the polytomous discrimination index.
- Author
-
Dover, Douglas C., Islam, Sunjidatul, Westerhout, Cynthia M., Moore, Linn E., Kaul, Padma, and Savu, Anamaria
- Subjects
MULTIPLE comparisons (Statistics) ,MEDICAL research ,REGRESSION analysis ,BIG data ,RESEARCH ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding ,LOGISTIC regression analysis - Abstract
Polytomous regression models generalize logistic models for the case of a categorical outcome variable with more than two distinct categories. These models are currently used in clinical research, and it is essential to measure their abilities to distinguish between the categories of the outcome. In 2012, van Calster et al proposed the polytomous discrimination index (PDI) as an extension of the binary discrimination c-statistic to unordered polytomous regression. The PDI is a summary of the simultaneous discrimination between all outcome categories. Previous implementations of the PDI are not capable of running on "big data." This article shows that the PDI formula can be manipulated to depend only on the distributions of the predicted probabilities evaluated for each outcome category and within each observed level of the outcome, which substantially improves the computation time. We present a SAS macro and R function that can rapidly evaluate the PDI and its components. The routines are evaluated on several simulated datasets after varying the number of categories of the outcome and size of the data and two real-world large administrative health datasets. We compare PDI with two other discrimination indices: M-index and hypervolume under the manifold (HUM) on simulated examples. We describe situations where the PDI and HUM, indices based on multiple comparisons, are superior to the M-index, an index based on pairwise comparisons, to detect predictions that are no different than random selection or erroneous due to incorrect ranking. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial.
- Author
-
McAlister, Finlay A., Zheng, Yinggan, Westerhout, Cynthia M., Buse, John B., Standl, Eberhard, McGuire, Darren K., Van de Werf, Frans, Green, Jennifer B., Armstrong, Paul W., and Holman, Rury R.
- Subjects
TYPE 2 diabetes ,VENTRICULAR ejection fraction ,CARDIOVASCULAR diseases ,GLYCEMIC control ,SECONDARY analysis ,CLINICAL trial registries - Abstract
Aims: Whether glycaemic control is associated with cardiovascular outcomes in patients with type 2 diabetes (T2D) is unclear. Consequently, we assessed the relationship between glycated haemoglobin (HbA1c) and cardiovascular outcomes in a placebo‐controlled randomized trial which demonstrated no cardiovascular effect of sitagliptin in patients with T2D and atherosclerotic vascular disease. Methods and results: Secondary analysis of 14 656 TECOS participants with time to event analyses using multivariable Cox proportional hazard models. During a median 3.0 (interquartile range 2.3–3.8) year follow‐up, 456 (3.1% of 14 656) patients had first hospitalization for heart failure (HF), 1084 (11.5%) died, 1406 (9.6%) died or were hospitalized for HF, and 1689 (11.5%) had a non‐HF cardiovascular event (cardiovascular death, non‐fatal stroke, non‐fatal myocardial infarction, or hospitalization for unstable angina). Associations between baseline or time‐varying HbA1c and cardiovascular outcomes were U‐shaped, with the lowest risk when HbA1c was around 7%. Each one‐unit increase in the time‐varying HbA1c above 7% was associated with an adjusted hazard ratio (HR) of 1.21 [95% confidence interval (CI) 1.11–1.33] for first HF hospitalization, 1.11 (1.03–1.21) for all‐cause death, 1.18 (1.09–1.26) for death or HF hospitalization, and 1.10 (1.02–1.17) for non‐HF cardiovascular events. Each one‐unit decrease in the time‐varying HbA1c below 7% was associated with an adjusted HR of 1.35 (95% CI 1.12–1.64) for first HF hospitalization, 1.37 (1.16–1.61) for death, 1.42 (1.23–1.64) for death or HF hospitalization, and 1.22 (1.06–1.41) for non‐HF cardiovascular events. Conclusion: Glycated haemogobin exhibits a U‐shaped association with cardiovascular outcomes in patients with T2D and atherosclerotic vascular disease, with nadir around 7%. Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT00790205. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Influence of Clinical Trials of Acute Coronary Syndrome Beyond the Primary Hypothesis: A Systematic Review.
- Author
-
Luoma, Leiah M., Westerhout, Cynthia M., Granger, Christopher B., and Armstrong, Paul W.
- Published
- 2020
- Full Text
- View/download PDF
18. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial.
- Author
-
Fiuzat, Mona, Ezekowitz, Justin, Alemayehu, Wendimagegn, Westerhout, Cynthia M., Sbolli, Marco, Cani, Dario, Whellan, David J., Ahmad, Tariq, Adams, Kirkwood, Piña, Ileana L., Patel, Chetan B., Anstrom, Kevin J., Cooper, Lawton S., Mark, Daniel, Leifer, Eric S., Felker, G. Michael, Januzzi, James L., and O'Connor, Christopher M.
- Published
- 2020
- Full Text
- View/download PDF
19. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
- Author
-
Pieske, Burkert, Patel, Mahesh J., Westerhout, Cynthia M., Anstrom, Kevin J., Butler, Javed, Ezekowitz, Justin, Hernandez, Adrian F., Koglin, Joerg, Lam, Carolyn S.P., Ponikowski, Piotr, Roessig, Lothar, Voors, Adriaan A., O'Connor, Christopher M., Armstrong, Paul W., and VICTORIA Study Group
- Subjects
HEART failure ,CORONARY disease ,GUANYLATE cyclase ,NATRIURETIC peptides ,GLOBAL studies ,GLOMERULAR filtration rate - Abstract
Aim: Describe the distinguishing features of heart failure (HF) patients with reduced ejection fraction (HFrEF) in the VICTORIA (Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction) trial.Methods and Results: Key background characteristics were evaluated in 5050 patients randomized in VICTORIA and categorized into three cohorts reflecting their index worsening HF event. Differences within the VICTORIA population were assessed and compared with PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) and COMMANDER HF (A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction, or Stroke in Participants with Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure). VICTORIA patients had increased risk of mortality and rehospitalization: New York Heart Association class (40% class III), atrial fibrillation (45%), diabetes (47%), hypertension (79%) and mean estimated glomerular filtration rate of 61.5 mL/min/1.73 m2 . Baseline standard of HF care was very good: 60% received triple therapy. Their N-terminal pro-B-type natriuretic peptide was 3377 pg/mL [interquartile range (IQR) 1992-6380]. Natriuretic peptides were 30% higher level in the 67% patients with HF hospitalization <3 months, compared to those within 3-6 months of HF hospitalization and those randomized after recent outpatient intravenous diuretic therapy. Overall the median MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) risk score in VICTORIA was 23 (IQR 18-27) as compared to the MAGGIC risk score in PARADIGM-HF of 20 (IQR 16-24).Conclusions: VICTORIA comprises a broadly generalizable high-risk population of three unique clinical strata of worsening chronic HFrEF despite very good HF therapy. VICTORIA will establish the role of vericiguat, a soluble guanylate cyclase stimulator, in HFrEF. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
20. Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice.
- Author
-
Du, Amy X., Westerhout, Cynthia M., McAlister, Finlay A., Shanks, Miriam, Oudit, Gavin Y., Paterson, David Ian, Hanninen, Mikael, Thomas, Jissy, and Ezekowitz, Justin A.
- Published
- 2019
- Full Text
- View/download PDF
21. Composite End Points in Clinical Research: A Time for Reappraisal.
- Author
-
Armstrong, Paul W. and Westerhout, Cynthia M.
- Published
- 2017
- Full Text
- View/download PDF
22. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
- Author
-
Josse, Robert G., Majumdar, Sumit R., Zheng, Yinggan, Adler, Amanda, Bethel, M. Angelyn, Buse, John B., Green, Jennifer B., Kaufman, Keith D., Rodbard, Helena W., Tankova, Tsvetalina, Westerhout, Cynthia M., Peterson, Eric D., Holman, Rury R., and Armstrong, Paul W.
- Subjects
DIAGNOSIS of diabetes ,TREATMENT of diabetes ,PEOPLE with diabetes ,DIABETES ,SITAGLIPTIN - Abstract
Aim To examine fracture incidence among participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin ( TECOS). Research design and methods We used data from 14 671 participants in the TECOS study who were randomized double-blind to sitagliptin (n = 7332) or placebo (n = 7339). Cumulative fracture incidence rates were calculated and their association with study treatment assignment was examined using multivariable Cox proportional hazards regression. Results The baseline mean (standard deviation) participant age was 65.5 (8.0) years, diabetes duration was 11.6 (8.1) years and glycated haemoglobin level was 7.2 (0.5)% [55.2 (5.5) mmol/mol], and 29.3% of participants were women and 32.1% were non-white. During 43 222 person-years' follow-up, 375 (2.6%; 8.7 per 1000 person-years) had a fracture; 146 were major osteoporotic fractures (hip, n = 34; upper extremity, n = 81; and clinical spine, n = 31). Adjusted analyses showed fracture risk increased independently with older age ( P < .001), female sex ( P < .001), white race ( P < .001), lower diastolic blood pressure ( P < .001) and diabetic neuropathy ( P = .003). Sitagliptin, compared with placebo, was not associated with a higher fracture risk [189 vs 186 incident fractures: unadjusted hazard ratio ( HR) 1.01, 95% confidence interval ( CI) 0.82 to 1.23, P = .944; adjusted HR 1.03, P = .745], major osteoporotic fractures ( P = .673) or hip fractures ( P = .761). Insulin therapy was associated with a higher fracture risk ( HR 1.40, 95% CI 1.02-1.91; P = .035), and metformin with a lower risk ( HR 0.76, 95% CI 0.59-0.98; P = .035). Conclusion Fractures were common among people with diabetes in the TECOS study, but were not related to sitagliptin therapy. Insulin and metformin treatment were associated with higher and lower fracture risks, respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
23. Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar.
- Author
-
Déry, Jean‐Pierre, Mahaffey, Kenneth W., Tricoci, Pierluigi, White, Harvey D., Podder, Mohua, Westerhout, Cynthia M., Moliterno, David J., Harrington, Robert A., Chen, Edmond, Strony, John, Van de Werf, Frans, Ziada, Khaled M., Held, Claes, Aylward, Philip E., Armstrong, Paul W., and Rao, Sunil V.
- Published
- 2016
- Full Text
- View/download PDF
24. Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction.
- Author
-
Bainey, Kevin R., Fresco, Claudio, Yinggan Zheng, Halvorsen, Sigrun, Carvalho, Antonio, Ostojic, Miodrag, Goldstein, Patrick, Gershlick, Anthony H., Westerhout, Cynthia M., Van de Werf, Frans, Armstrong, Paul W., Zheng, Yinggan, and STREAM Investigators
- Subjects
MYOCARDIAL infarction ,MYOCARDIAL reperfusion ,PERCUTANEOUS coronary intervention ,CORONARY disease ,FIBRINOLYSIS ,MYOCARDIAL infarction diagnosis ,MYOCARDIAL infarction-related mortality ,MYOCARDIAL infarction treatment ,CARDIOVASCULAR system ,COMPARATIVE studies ,ELECTROCARDIOGRAPHY ,RESEARCH methodology ,MEDICAL care ,MEDICAL care research ,MEDICAL cooperation ,HEALTH outcome assessment ,RESEARCH ,RISK assessment ,SURVIVAL analysis (Biometry) ,TICLOPIDINE ,TIME ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,PLATELET aggregation inhibitors ,ENOXAPARIN - Abstract
Objective: Uncertainty exists concerning the relative merits of pharmacological versus mechanical coronary reperfusion in patients presenting early with ST-elevation myocardial infarction (STEMI) with extensive myocardium at risk. Accordingly, we investigated whether the extent of baseline ST-segment shift was related to the response of either reperfusion modality in patients with STEMI presenting within 3 h of symptoms.Methods: We analysed baseline ECGs from 1859 patients enrolled in the STrategic Reperfusion Early After Myocardial Infarction (STREAM) trial. The sum of ST-segment elevation (∑STE) and ST-segment deviation (∑STD) was categorised into quartiles and associations with the primary endpoint (30-day death/shock/congestive heart failure/re-myocardial infarction) for each reperfusion strategy (early fibrinolysis vs primary percutaneous coronary intervention) were explored.Results: Overall, there was a progressive rise in the 30-day primary endpoint according to quartiles of baseline ∑STE (10.3% (0-5 mm), 12.4% (5.5-8.5 mm), 12.1% (9-13.5 mm), 17.6% (> 14.0 mm), p = 0.008) and ∑STD (9.0% (0-9 mm), 13.5% (9.5-14 mm), 14.7% (14.5-20 mm), 15.3% (> 20 mm), p = 0.019). Both ∑STE and ∑STD were associated with the primary endpoint (∑STE: p = 0.071; ∑STD: p = 0.024). However, there was no interaction between quartiles of baseline ∑STE or ∑STD and efficacy of either reperfusion strategy on the 30-day clinical outcomes (∑STE: p (interaction) = 0.696; ∑STD: p (interaction) = 0.542).Conclusions: These data demonstrate an association between ∑STE or ∑STD on the baseline ECG and clinical events at 30 days following reperfusion therapy in STEMI. More importantly, the response to different reperfusion strategies was not influenced by the extent of jeopardised myocardium.Trial Registration Number: NCT00623623; Post-results. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
25. Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery.
- Author
-
Diepen, Sean, Tricoci, Pierluigi, Podder, Mohua, Westerhout, Cynthia M., Aylward, Philip E., Held, Claes, Van de Werf, Frans, Strony, John, Wallentin, Lars, Moliterno, David J., White, Harvey D., Mahaffey, Kenneth W., Harrington, Robert A., and Armstrong, Paul W.
- Published
- 2015
- Full Text
- View/download PDF
26. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials.
- Author
-
Bakal, Jeffrey A., Westerhout, Cynthia M., and Armstrong, Paul W.
- Subjects
CARDIOVASCULAR diseases ,RANDOMIZED controlled trials ,CLINICAL trials ,SAMPLE size (Statistics) ,HEALTH outcome assessment ,CARDIOVASCULAR disease treatment ,BIOLOGICAL assay ,COMPARATIVE studies ,EXPERIMENTAL design ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,STATISTICS ,DATA analysis ,EVALUATION research ,TREATMENT effectiveness ,KAPLAN-Meier estimator - Abstract
Composite endpoints are commonly used in cardiovascular clinical trials. When using a composite endpoint a subject is considered to have an event when the first component endpoint has occurred. The use of composite endpoints offers the ability to incorporate several clinically important endpoint events thereby augmenting the event rate and increasing statistical power for a given sample size. One assumption of the composite is that all component events are of equal clinical importance. This assumption is rarely achieved given the diversity of component endpoints included. One means of adjusting for this diversity is to adjust the outcomes using severity weights determined a priori. The use of a weighted endpoint also allows for the incorporation of multiple endpoints per patient. Although weighting the outcomes lowers the effective number of events, it offers additional information that reduces the variance of the estimate. We created a series of simulation studies to examine the effect on power as the individual components of a typical composite were changed. In one study, we noted that the weighted composite was able to offer discriminative power when the component outcomes were altered, while the traditional method was not. In the other study, we noted that the weighted composite offered a similar level of power to the traditional composite when the change was driven by the more severe endpoints. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
27. Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis.
- Author
-
Abdel-Qadir, Husam, Yan, Andrew T., Tan, Mary, Borgia, Francesco, Piscione, Federico, Di Mario, Carlo, Halvorsen, Sigrun, Cantor, Warren J., Westerhout, Cynthia M., Scheller, Bruno, Le May, Michel R., Fernandez-Aviles, Francisco, Sánchez, Pedro L., Lee, Douglas S., and Goodman, Shaun G.
- Subjects
FIBRINOLYSIS ,META-analysis ,RANDOMIZED controlled trials ,MYOCARDIAL infarction ,EARLY medical intervention ,STROKE ,PERCUTANEOUS coronary intervention - Abstract
Background: Randomised controlled trials have demonstrated improved outcomes with an early invasive strategy compared with routine care after fibrinolysis among patients with ST-elevation myocardial infarction. However, it remains uncertain whether specific patient subsets derive differential benefit from an early invasive strategy.Methods: Using patient-level data from seven randomised trials, we studied the relationship between treatment assignment (early invasive vs standard care) and adverse cardiovascular events. The outcomes assessed were death/reinfarction at 30 days and at 1 year, as well as death/reinfarction/recurrent ischaemia, major bleeding and stroke at 30 days. The analyses were conducted in strata (age, sex, diabetes, prior infarction, Killip class, anterior infarction and time from symptom onset to fibrinolysis) to assess for an interaction between the stratifying variable and treatment assigned.Results: There were 101 deaths and 115 recurrent infarctions at 30 days in 3010 patients. There were no strata where an invasive strategy conferred a differential treatment effect. With the exception of a marginally significant interaction between Killip class and treatment for death/reinfarction at 30 days and 1 year (p values for interaction 0.044 and 0.038, respectively), no interactions between the stratifying variables and treatment assignment were observed.Conclusions: Benefit from an early invasive strategy after fibrinolysis for ST-elevation myocardial infarction is similar across patient subgroups stratified by these clinical characteristics. Therefore, prediction of risk and benefit from an early invasive strategy after fibrinolysis for ST-elevation myocardial infarction is best achieved by global risk evaluation rather than specific patient characteristics. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
28. Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged.
- Author
-
Gershlick, Anthony H., Westerhout, Cynthia M., Armstrong, Paul W., Huber, Kurt, Halvorsen, Sigrun, Steg, Philippe Gabriel, Ostojic, Miodrag, Goldstein, Patrick, Carvalho, Antonio C., Van de Werf, Frans, and Wilcox, Robert G.
- Subjects
MYOCARDIAL infarction treatment ,ANGIOPLASTY ,MYOCARDIAL reperfusion ,ECHOCARDIOGRAPHY ,CONGESTIVE heart failure ,CARDIOGENIC shock - Abstract
Objectives Primary percutaneous coronary intervention (P-PCI) is the preferred reperfusion option in ST-elevation myocardial infarction, but its benefits become attenuated as time to its potential delivery becomes prolonged. Based on the STrategic Reperfusion Early After Myocardial Infarction trial, we assessed the impact of increasing time delay on outcomes in patients randomised to a pharmacoinvasive strategy (PI) or P-PCI. Methods Thirty-day clinical outcomes were examined according to PCI-related delay (P-RD). Data from hospitals that enrolled >10 randomised patients were used and P-RD categorised as ≤55 min, >55-97 min and >97 min. Results Composite of death/congestive heart failure/ cardiogenic shock/myocardial infarction in PI and P-PCI arms occurred in 10.6% versus 10.3% (≤55 min, p=0.910); 13.9% versus 17.9% (>55-97 min, p=0.148) and 13.5% versus 16.2% (>97 min, p=0.470), respectively. While there was no worsening of outcomes for PI across the P-RD spectrum, this occurred in the P-PCI arm (p(trend)=0.038). For P-RD <55 min, fewer events tended to occur with P-PCI than PI. Conversely, as P-RD increased to >55 min, PI-assigned patients had better outcomes than P-PCI, suggesting an event-free advantage with PI as P-RD increased (p (interaction)=0.094). Analysing P-RD continuously showed that for every 10-min increment there was an increasing trend towards benefit among PI-assigned patients (p(interaction)=0.073). Conclusions As P-RD increased, PI outcomes became superior to P-PCI when P-RD is prolonged and exceeds guideline-mandated times. In such circumstances, a PI strategy may provide an alternative reperfusion option. Adverse time delays for delivery of P-PCI should be considered when evaluating reperfusion strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
29. Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial.
- Author
-
Bakal, Jeffrey A., Roe, Matthew T., Ohman, E. Magnus, Goodman, Shaun G., Fox, Keith A.A., Zheng, Yinggan, Westerhout, Cynthia M., Hochman, Judith S., Lokhnygina, Yuliya, Brown, Eileen B., and Armstrong, Paul W.
- Abstract
Aims Several methods provide new insights into understanding clinical trial composite endpoints, using both conventional and novel methods. The TRILOGY ACS trial is used as a contemporary example to prospectively compare these methods side by side. Methods and results The traditional time-to-first-event, Andersen–Gill recurrent events method, win ratio, and a weighted composite endpoint (WCE) are compared using the randomized, active-control TRILOGY ACS trial. This trial had a neutral result and randomized 9326 patients managed without coronary revascularization within 10 days of their acute coronary syndrome to receive either prasugrel or clopidogrel and followed them for up to 30 months. The traditional composite, win ratio, and WCE demonstrated no significant survival advantage for prasugrel, whereas the Andersen–Gill method demonstrated a statistical advantage for prasugrel [hazard ratio (HR), 0.86 (95% CI, 0.72–0.97)]. The traditional composite used 73% of total patient events; 40% of these were derived from the death events. The win ratio used 66% of total events; deaths comprised 57% of these. Both Andersen–Gill and WCE methods used all events in all participants; however, with the Andersen–Gill method, death comprised 41% of the proportion of events, whereas with the WCE method, death comprised 64% of events. Conclusion This study addresses the relative efficiency of various methods for assessing clinical trial events comprising the composite endpoint. The methods accounting for all events, in particular those incorporating their clinical relevance, appear most advantageous, and may be useful in interpreting future trials. This clinical and statistical advantage is especially evident with long-term follow-up where multiple non-fatal events are more common. Clinical Trial Registration NCT00699998. [ABSTRACT FROM PUBLISHER]
- Published
- 2015
- Full Text
- View/download PDF
30. Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: Insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial.
- Author
-
Toleva, Olga, Westerhout, Cynthia M., Senaratne, Manohara P.J., Bode, Christoph, Lindroos, Magnus, Sulimov, Vitaly A., Montalescot, Gilles, Newby, L. Kristin, Giugliano, Robert P., Werf, Frans, and Armstrong, Paul W.
- Published
- 2014
- Full Text
- View/download PDF
31. Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial.
- Author
-
Maleki, Neda Dianati, Van de Werf, Frans, Goldstein, Patrick, Adgey, Jennifer A., Lambert, Yves, Sulimov, Vitaly, Rosell-Ortiz, Fernando, Gershlick, Anthony H., Yinggan Zheng, Westerhout, Cynthia M., and Armstrong, Paul W.
- Subjects
MYOCARDIAL infarction ,REPERFUSION ,ELECTROCARDIOGRAPHY ,TENECTEPLASE ,ANGIOPLASTY ,CORONARY artery surgery - Abstract
Background We evaluated the prespecified endpoint, aborted myocardial infarction (AbMI), according to the use of a pharmacoinvasive (PI) strategy versus primary percutaneous coronary intervention (PCI) in 1754 patients randomised within 3 h of symptom onset in the STrategic Reperfusion Early After Myocardial infarction (STREAM) trial. Methods Based on sequential ECG's and biomarkers, AbMI was defined as ST-elevation resolution =50% (90 min posttenecteplase (TNK) in the PI arm or 30 min postprimary PCI) with minimal biomarker rise. Results In the PI arm 11.1% (n=99) had AbMI versus 6.9% (n=59) in primary PCI arm ( p<0.01). In a multivariable model, AbMI patients overall had less baseline SST-deviation, fewer baseline Q-waves and shorter total ischaemic times. PI AbMI patients had faster time to TNK (90 vs 100 min, p=0.015): total ischaemic time was 100 min longer in primary PCI AbMI patients and no difference in ischaemic time existed between AbMI and non-AbMI patients within this group. Although no significant interaction between treatment and AbMI on the composite endpoint of death/shock/congestive heart failure/recurrent MI occurred (p=0.292), PI AbMI patients had a lower incidence in this endpoint than non- AbMI patients (5.1 vs 12%, p=0.038); this was not evident in primary PCI patients. Forty-five patients (ie, 2.5%) had masquerading MI with minimal biomarker elevation and no evolution in baseline ST-elevation. Conclusions A PI strategy of early fibrinolysis more frequently aborts MI than primary PCI. Such PI patients had more favourable outcomes as compared with non- AbMIs. Diligent review of ECG evolution in STEMI distinguishes AbMI from infarct masquerade. Clinical Trials.gov ID NCT00623623. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
32. Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint.
- Author
-
Bakal, Jeffrey A., Westerhout, Cynthia M., Cantor, Warren J., Fernández-Avilés, Francisco, Welsh, Robert C., Fitchett, David, Goodman, Shaun G., and Armstrong, Paul W.
- Abstract
Aims The selection of optimal endpoints for cardiovascular clinical trials continues to be challenging. We examined an alternative interpretation of a series of trials when the individual event severity is considered. Methods and results We analysed three contemporary myocardial infarction (MI) trials of early percutaneous coronary intervention after fibrinolysis, using a weighted composite method. This method allows the examination of the heterogeneity in the direction and magnitude of component endpoints, and multiple events (vs. first event). We incorporated a physician-assessed severity of each component endpoint in all patients for the five-item composite in the largest study, Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI), which enrolled 1059 ST-elevation MI patients. The traditional approach yielded event-free survival probabilities of 0.89 [95% confidence interval (CI) 0.86–0.91] for the early invasive arm and 0.83 (95% CI 0.79–0.86) for the standard care arm (P = 0.004). After accounting for the clinician-investigator-determined weights, the effective survival probabilities were 0.93 (95% CI 0.91–0.95) for the early invasive arm and 0.93 (95% CI 0.90–0.95) with no significant difference (P = 0.54). The same pattern was observed in the three-trial cohort using a four-item composite with an observed improvement in event-free survival outcomes (P = 0.01), which was no longer apparent after the severity weights were considered (P = 0.44). Conclusion This analysis highlights the importance of considering the relative severity and multiple events in the evaluation of a clinical trial. [ABSTRACT FROM PUBLISHER]
- Published
- 2013
- Full Text
- View/download PDF
33. Acute Heart Failure.
- Author
-
Ezekowitz, Justin A., Jia Hu, Delgado, Diego, Hernandez, Adrian F., Kaul, Padma, Leader, Rolland, Proulx, Guy, Virani, Sean, White, Michel, Zieroth, Shelley, O'Connor, Christopher, Westerhout, Cynthia M., and Armstrong, Paul W.
- Published
- 2012
- Full Text
- View/download PDF
34. Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial.
- Author
-
Siha, Hany, Das, Debraj, Yuling Fu, Yinggan Zheng, Westerhout, Cynthia M., Storey, Robert F., James, Stefan, Wallentin, Lars, and Armstrong, Paul W.
- Subjects
ACUTE coronary syndrome ,ELECTROCARDIOGRAPHY ,MORTALITY ,MULTIVARIATE analysis ,CONFIDENCE intervals ,HEALTH outcome assessment - Abstract
Background: Baseline Q waves may provide additional value compared with time from the onset of symptoms in predicting outcomes for patients with ST-segment elevation. We evaluated whether baseline Q waves superseded time from symptom onset as a prognostic marker of one-year mortality in patients with ST-segment elevation acute coronary syndrome. Our study was derived from data from patients undergoing primary percutaneous coronary intervention within 24 hours in the PLATelet inhibition and patient Outcomes trial Methods: Q waves on the baseline electrocardiogram were evaluated by a blinded core laboratory. We assessed the associations between baseline Q waves and time from symptom onset to percutaneous coronary intervention with peak biomarkers, ST-segment resolution on the discharge electrocardiogram, and one-year all-cause and vascular mortality. Results: Of 4341 patients with ST-segment elevation, 46% had baseline Q waves. Compared to those without Q waves, those with baseline Q waves were older, more frequently male, had higher heart rates, more advanced Killip class and had a longer time between the onset of symptoms and percutaneous coronary intervention. They also had higher one-year all-cause mortality than patients without baseline Q waves (baseline Q waves: 4.9%; no baseline Q waves: 2.8%; hazard ratio [HR] 1.78, 95% confidence interval [CI] 1.29-2.45, p < 0.001). Complete ST-segment resolution was greatest and all-cause mortality lowest among those with symptom onset three hours or less before percutaneous coronary intervention and no baseline Q waves. After multivariable adjustment, baseline Q waves, but not time from symptom onset, were associated with a significant increase in all-cause mortality (adjusted HR 1.42, 95% CI 1.10-2.01, p = 0.046) and vascular mortality (adjusted HR 1.58, 95% CI 1.09-2.28, p = 0.02). Interpretation: The presence of baseline Q waves provides useful additional prognostic insight into the clinical outcome of patients with ST-segment elevation. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
35. ST-Elevation Acute Coronary Syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
- Author
-
Armstrong, Paul W., Siha, Hany, Yuling Fu, Westerhout, Cynthia M., Steg, Gabriel, James, Stefan K., Storey, Robert F., Horrow, Jay, Katus, Hugo, Clemmensen, Peter, Harrington, Robert A., and Wallentin, Lars
- Published
- 2012
- Full Text
- View/download PDF
36. Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial.
- Author
-
Huber, Kurt, Holmes, David R., van 't Hof, Arnoud W., Montalescot, Gilles, Aylward, Philip E., Betriu, G. Amadeo, Widimsky, Petr, Westerhout, Cynthia M., Granger, Christopher B., and Armstrong, Paul W.
- Abstract
Aims: Controversy exists regarding the early use of glycoprotein IIb/IIIa inhibitors (GPIs) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial provides a unique opportunity to examine early vs. late or non-use of GPIs in a large STEMI cohort treated with PCI. [ABSTRACT FROM PUBLISHER]
- Published
- 2010
- Full Text
- View/download PDF
37. Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial.
- Author
-
Toma, Mustafa, Buller, Christopher E., Westerhout, Cynthia M., Fu, Yuling, O'Neill, William W., Holmes, David R., Hamm, Christian W., Granger, Christopher B., and Armstrong, Paul W.
- Abstract
Aims: To examine the incidence of and propensity for non-culprit interventions performed at the time of the primary percutaneous coronary intervention (PCI) and its association with 90-day outcomes. [ABSTRACT FROM PUBLISHER]
- Published
- 2010
38. Resolution of ST-segment depression: a new prognostic marker in ST-segment elevation myocardial infarction.
- Author
-
Tjandrawidjaja, Michael C., Fu, Yuling, Westerhout, Cynthia M., White, Harvey D., Todaro, Thomas G., Van de Werf, Frans, Mahaffey, Kenneth W., Wagner, Galen S., Granger, Christopher B., and Armstrong, Paul W.
- Abstract
Aims: To evaluate the prognostic impact of ST depression resolution among patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI in the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. [ABSTRACT FROM PUBLISHER]
- Published
- 2010
39. Acute heart failure in the emergency department: Short and long-term outcomes of elderly patients with heart failure
- Author
-
Ezekowitz, Justin A., Bakal, Jeffery A., Kaul, Padma, Westerhout, Cynthia M., and Armstrong, Paul W.
- Subjects
HEART failure ,HOSPITAL emergency services ,HOSPITAL care ,HEART disease related mortality ,CARDIAC patients ,RISK assessment - Abstract
Abstract: Aims: Previous epidemiologic studies of acute heart failure (AHF) have involved patients admitted to hospital and fail to account for that unknown proportion discharged directly from the emergency department (ED). We examined discharge rates, and whether outcomes, including mortality, differed based on admission status in AHF. Methods and results: This population-based cohort included all patients ≥65 years presenting to an Alberta ED with HF (ICD9-CM 428.x; 1998 to 2001). Patients were either not admitted (Not-ADM) or directly admitted to hospital (ADM) and followed for one-year. Of 10,415 AHF patients evaluated in the ED, 35% were Not-ADM whereas 65% were ADM. Thirty days after ED presentation the rates of death, re-ED or initial/re-hospitalisation were 3.3%, 44% and 19% for Not-ADM, and 10.9%, 33% and 21% for the ADM patients, respectively (all p <0.0001). At one-year, the rates of death, re-ED or initial/re-hospitalisation were 20%, 82% and 58% for Not-ADM, and 34%, 72% and 60% for ADM, respectively (all p <0.0001). Conclusions: One third of AHF patients were not immediately admitted after an ED visit but most present again to the ED, two-thirds were hospitalised and 20% died within the first year. Our findings provide new impetus to undertake risk assessment and treatment strategies in the ED for AHF. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
40. Differences in admission rates and outcomes between men and women presenting to emergency departments with coronary syndromes.
- Author
-
Kaul, Padma, Wei-Ching Chang, Westerhout, Cynthia M., Graham, Michelle M., and Armstrong, Paul W.
- Subjects
SICK people ,CORONARY disease ,ANGINA pectoris ,SOCIAL factors ,DEATH ,DISEASES in women ,THERAPEUTICS ,OUTPATIENT medical care - Abstract
Background: Previous studies examining sex-related differences in the treatment of coronary artery disease have focused on patients in hospital. We sought to examine sexrelated differences at an earlier point in care - presentation to the emergency department. Methods: We collected data on ambulatory care and hospital admissions for 54 134 patients (44% women) who presented to an emergency department in Alberta between July 1998 and March 2001 because of acute myocardial infarction, unstable angina, stable angina or chest pain. We used logistic regression and Cox regression analyses to determine sexspecific associations between the likelihood of discharge from the emergency department or coronary revascularization within 1 year and 1-year mortality after adjusting for age, comorbidities and socioeconomic factors. Results: Following the emergency department visit, 91.3% of patients with acute myocardial infarction, 87.4% of those with unstable angina, 40.7% of those with stable angina and 19.8% of those with c st pain were admitted to hospital. Women were more likely than men to be discharged from the emergency department: adjusted odds ratio (and 95% confidence interval [CI]) 2.25 (1.75-2.90) for acute myocardial infarction, 1.71 (1.45-2.01) for unstable angina, 1.33 (1.15-1.53) for stable angina and 1.46 (1.36-1.57) for chest pain. Women were less likely than men to undergo coronary revascularization within 1 year: adjusted odds ratio (and 95% CI) 0.65 (0.57-0.73) for myocardial infarction, 0.39 (0.35-0.44) for unstable angina, 0.35 (0.29-0.42) for stable angina and 0.32 (0.27-0.37) for chest pain. Female sex had no impact on 1-year mortality among patients with acute myocardial infarction; it was associated with a decreased 1-year mortality among patients with unstable angina, stable angina and chest pain: adjusted hazard ratio (and 95% CI) 0.60 (0.46-0.78), 0.60 (0.46-0.78) and 0.74 (0.63-0.87) respectively. Interpretation: Women presenting to the emergency department with coronary syndromes are less likely than men to be admitted to an acute care hospital and to receive coronary revascularization procedures. These differences do not translate into worse outcomes for women in terms of 1-year mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
41. Primary Percutaneous Coronary Intervention Compared With Fibrinolysis for Myocardial Infarction in Diabetes Mellitus.
- Author
-
Timmer, Jorik R., Ottervanger, Jan Paul, De Boer, Menko-Jan, Boersma, Eric, Grines, Cindy L., Westerhout, Cynthia M., Simes, R. John, Granger, Christopher B., and Zijlstra, Felix
- Subjects
MYOCARDIAL infarction treatment ,CARDIAC surgery ,FIBRINOLYSIS ,MYOCARDIAL reperfusion ,MORTALITY ,DIABETES - Abstract
The article compares percutaneous coronary intervention with fibrinolysis for treatment of ST-segment elevation myocardial infarction (PCI)in patients with diabetes mellitus. Results reveal that diabetic patients with ST-segment elevation myocardial infarction treated with reperfusion therapy have increased mortality compared with patients without diabetes. The beneficial effects of primary PCI compared with fibrinolysis in diabetic patients are in harmony with effects in nondiabetics.
- Published
- 2007
- Full Text
- View/download PDF
42. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups.
- Author
-
Hernández, Adrián V., Westerhout, Cynthia M., Steyerberg, Ewout W., Loannidis, John P. A., Bueno, Hector, White, Harvey, Theroux, Pierre, Moliterno, David J., Armstrong, Paul W., Califf, Robert M., Wallentin, Lars C., Simoons, Maarten L., and Boersma, Eric
- Subjects
PLATELET glycoprotein GPIIb-IIIa complex ,HEART diseases ,SYNDROMES ,AGE groups ,META-analysis ,CLINICAL trials - Abstract
Objective: To investigate whether the beneficial and harmful effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST elevation acute coronary syndromes (NSTE-ACS) depend on age. Methods: A meta-analysis of six trials of platelet glycoprotein IIb/IIIa receptor blockers in patients with NSTE-ACS (PRISM, PRISM-PLUS, PARAGON-A, PURSUIT, PARAGON-B, GUSTO IV-ACS; n = 31 402) was performed. We applied multivariable logistic regression analyses to evaluate the drug effects on death or non-fatal myocardial infarction at 30 days, and on major bleeding, by age subgroups (<60, 60-69, 70-79, ⩾80 years). We quantified the reduction of death or myocardial infarction as the number needed to treat (NNT), and the increase of major bleeding as the number needed to harm (NNH). Results: Subgroups had 11 155 (35%), 9727 (31%), 8468 (27%) and 2049 (7%) patients, respectively. The relative benefit of platelet glycoprotein Ib/IIIa receptor blockers did not differ significantly (p=0.5) between age subgroups (OR (95% CI) for death or myocardial infarction: 0.86 (0.74 to 0.99), 0.90 (0.80 to 1.02), 0.97(0.86 to 1.10), 0.90 (0.73 to 1.16); overall 0.91 (0.86 to 0.99). ORs for major bleeding were 1.9 (1.3 to 2.8), 1.9 (1.4 to 2.7), 1 .6 (1.2 to 2.1) and 2.5 (1.5-4.1). Overall NNT was 105, and overall NNH was 90. The oldest patients had larger absolute increases in major bleeding, but also had the largest absolute reductions of death or myocardial infarction. Patients ⩾80 years had half of the NNT and a third of the NNH of patients <60 years. Conclusions: In patients with NSTE-ACS, the relative reduction of death or non-fatal myocardial infarction with platelet glycoprotein IIb/IIIa receptor blockers was independent of patient age. Larger absolute outcome reductions were seen in older patients, but with a higher risk of major bleeding. Close monitoring of these patients is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
43. Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes.
- Author
-
Westerhout, Cynthia M., Hernández, Adrián V., Steyerberg, Ewout W., Bueno, Héctor, White, Harvey, Théroux, Pierre, Moliterno, David J., Armstrong, Paul W., Califf, Robert M., Wallentin, Lars C., Simoons, Maarten L., and Boersma, Eric
- Abstract
Aims Stroke is an uncommon but serious complication after non-ST-segment elevation acute coronary syndrome (NSTE-ACS). We aimed to identify predictors of stroke within 30 days in patients who suffered NSTE-ACS. [ABSTRACT FROM PUBLISHER]
- Published
- 2006
- Full Text
- View/download PDF
44. Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction.
- Author
-
Chang, Wei-Ching, Kaul, Padma, Fu, Yuling, Westerhout, Cynthia M., Granger, Christopher B., Mahaffey, Kenneth W., Wallentin, Lars, Van de Werf, Frans, and Armstrong, Paul W.
- Abstract
Aims To demonstrate the feasibility and clinical utility of developing dynamic risk assessment models for ST-segment elevation myocardial infarction (STEMI) patients. [ABSTRACT FROM PUBLISHER]
- Published
- 2006
- Full Text
- View/download PDF
45. Impact of Sex on Long-term Mortality From Acute Myocardial Infarction vs Unstable Angina.
- Author
-
Wei-Ching Chang, Constance M., Kaul, Padma, Westerhout, Cynthia M., Graham, Michelle M., Yuling Fu, Michelle M., Chowdhury, Tapan, and Armstrong, Paul W.
- Subjects
MORTALITY -- Sex differences ,MYOCARDIAL infarction ,HEART disease related mortality ,ANGINA pectoris ,COHORT analysis - Abstract
Background: Patient sex has been shown to differentially affect mortality from unstable angina (UA) and acute myocardial infarction (AMI). However, to our knowledge, no prior population-based studies have examined both cohorts simultaneously to explain this intriguing variation. Hence, we undertook to explore and explain sex differences in 5-year mortality after UA and AMI. Methods: We used an administrative database of 22 967 patients with AMI and 8441 patients with UA discharged from acute care hospitals in Alberta between April 1, 1993, and March 31, 2000. Results: Women were older with more baseline comorbidities, more frequently had a diagnosis of UA, and had 30% lower relative odds of undergoing revascularization than men. Kaplan-Meier estimates of 5-year mortality were similar between sexes after UA (women vs men, 21.6% vs 19.5%; P = .09) but markedly higher for women after AMI (38.5% vs 26.6%, P<.001). After adjustment for baseline characteristics and revascularization, the hazard ratios (95% confidence intervals) for women vs men were 0.81 (0.72-0.92) after UA and 0.99 (0.93-1.05) after AMI. Only women younger than 65 years were at a significantly higher risk after AMI. The reasons for this difference in sex-related outcomes between UA and AMI may relate to greater disparities in the AMI cohort with respect to age, comorbidities, neighborhood incomes, and referrals to cardiovascular specialists. Conclusions: Relative to UA, AMI has a more serious impact on women than men, such that women have a survival advantage when afflicted with UA but lose that advantage with AMI. Additional investigation into the causes, treatment, and policy implications of the age-sex interaction is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
46. The Power of More Than One.
- Author
-
Armstrong, Paul W. and Westerhout, Cynthia M.
- Published
- 2013
- Full Text
- View/download PDF
47. Novel Biomarkers, ST-Elevation Resolution, and Clinical Outcomes Following Primary Percutaneous Coronary Intervention.
- Author
-
Shavadia, Jay S, Granger, Christopher B, Alemayehu, Wendimagegn, Westerhout, Cynthia M, Povsic, Thomas J, Van Diepen, Sean, Defilippi, Christopher, and Armstrong, Paul W
- Published
- 2020
- Full Text
- View/download PDF
48. Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction in Clinical Practice: Insights From the Vital Heart Response Registry.
- Author
-
Bainey, Kevin R., Armstrong, Paul W., Zheng, Yinggan, Brass, Neil, Tyrrell, Benjamin D., Leung, Raymond, Westerhout, Cynthia M., and Welsh, Robert C.
- Published
- 2019
- Full Text
- View/download PDF
49. The authors' reply:.
- Author
-
Hernandez, Adrian V., Westerhout, Cynthia M., Steyerberg, Ewout W., Loannidis, John P. A., Bueno, Hector, White, Harvey, Theroux, Pierre, Moliterno, David J., Armstrong, Paul W., Calif, Robert M., Wallentin, Lars C., Simoons, Maarten L., and Boersma, Eric
- Subjects
LETTERS to the editor ,GLYCOPROTEINS - Abstract
A response by Adrian V. Hernandez and colleagues is presented to a letter to the editor about their article on the effects of glycoprotein llb/llla inhibitors in patients with an acute coronary syndrome.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.